| Industry | Biopharmaceutical |
| Sector | New drug discovery |
| Fiscal year end | September 30 |
| Shares issued and outstanding | 44,660,062* |
| Stock purchase warrants | 1,609,309** |
| Stock options | 5,867,030** |
| Fully diluted | 52,050,127** |
| Cash | ~$25.7 million** |
| Debt | Nil** |
| Trading symbol | AVXL |
| 52-week range | $2.45 – $6.64* |
| Financial statements and filings | Anavex’s filings can be found on EDGAR. |
| Investor relations | 1-844-689-3939 ir@anavex.com |
| Transfer agent | Nevada Agency and Trust 50 West Liberty Street, Suite 880 Reno, Nevada 89501 Tel: (775) 322-0626 Fax: (775) 322-5623 Transfer agent email: info@natco.org Resident Agent email: corpserve@natco.org Web site: www.natco.org |
* As at May 10, 2018
**As at March 31, 2018
Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)